INNOVATIVE PRODUCTS BASED ON PASSIVE IMMUNIZATION BY MEANS OF ANTI-SPIKE SPECIFIC IMMUNOGLOBULINS Y, INTENDED FOR THE PREVENTION AND TREATMENT OF SARS COV2 INFECTION AND POST-VACCINATION COMPLICATIONS
The invention relates to the use of Anti S1 (Spike 1) specific IgY Immunoglobulin for the preparation of a product to be administered orally or as intranasal spray for pre- and post-exposure prophylaxis for the SARS-CoV-2 pathogen, which product comprises 40...60% anti S1 IgY, 20...25% Nattokinase,...
Gespeichert in:
Hauptverfasser: | , , , , , , |
---|---|
Format: | Patent |
Sprache: | eng ; rum |
Schlagworte: | |
Online-Zugang: | Volltext bestellen |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | The invention relates to the use of Anti S1 (Spike 1) specific IgY Immunoglobulin for the preparation of a product to be administered orally or as intranasal spray for pre- and post-exposure prophylaxis for the SARS-CoV-2 pathogen, which product comprises 40...60% anti S1 IgY, 20...25% Nattokinase, 5% Astaxanthin, 10% Glutathione, and Quercetin, respectively, 5% a combination of vitamin C/vitamin D3/Zinc and 3% Xylitol, the percentage being expressed by mass.
Invenţia se referă la utilizarea Imunoglobulinei IgY specifică Anti S1 (Spike 1) pentru prepararea unui produs cu administrare orală sau spray intranazal pentru profilaxia pre şi post-expunere la patogenul SARS-CoV-2, în care produsul cuprinde în procente masice 40...60% IgY anti S1, 20...25% Nattokinaza, 5% Astaxantin, 10% Glutation, respectiv, Quercetin, 5% combinaţie de vitamina C/vitamina D3/Zinc şi 3% xilitol. |
---|